Vyhledat léčivý přípravek pro vzácné onemocnění
Další možnosti vyhledávání
379 Výsledků
Účinné látky
- (+)N-hydroxy-N-(methylacylfulvene)urea
- (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl) amino)methyl)tetrahydrofuran-3,4-diol
- (3E,5E)-3,5-bis[(4-fluoro-3-nitrophenyl)methylidene]-1-(prop-2-enoyl)azepan-4-0ne
- 17-allylamino-17-demethoxygeldanamycin
- 18-(p-(131I)-iodophenyl)octadecyl phosphocholine
- 2-[(3S)-2,6-dioxopiperidin-3-yl]-4-{[(2-fluoro-4-{[3-(morpholin-4-yl)azetidin-1-yl]methyl} phenyl) methyl]amino}-1H-isoindole-1,3(2H)-dione-hydrogen chloride (1/1)
- 2-{[2-benzyl-4-(5-methyl-3H-imidazol-4-ylmethyl)-3-oxo-piperazine-1-carbonyl]- amino}-4methyl-pentanoic acid
- 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride
- 4-[[(1S)-1-(4, 8-Dichloro-1-oxo-2-phenyl-3-isoquinolyl) ethyl] amino]-8H- pyrido[2,3-d] pyrimidin-5-one]
- 4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indol
- 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine
- 6-(4-(tert-butyl)phenoxy)pyridin-3-amine
- 6-(4-(tert-butyl)phenoxy)pyridin-3-amine hydrochloride
- 6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-B-L-manno-heptopyranosyl]amino-9H-purine
- 6-thioguanine (oral liquid)
- A lentiviral vector pseudotyped by the Indiana serotype of the vesicular stomatitis virus G protein encoding an antigen derived from the Tax, HBZ, p12I and p30II HTLV-1 proteins
- A lentiviral vector pseudotyped by the New-Jersey serotype of the vesicular stomatitis virus G protein encoding an antigen derived from the Tax, HBZ, p12I and p30II HTLV-1 proteins
- A polymer based prodrug of bortezomib
- A-dmDT390-bisFv(UCHT1)
- Acadesine
- Acalabrutinib
- Adenovirus-Interferon gamma - coding DNA sequence
- Alemtuzumab
- Alisertib
- Allogeneic Epstein-Barr virus specific cytotoxic T lymphocytes
- Allogeneic T cells encoding an exogenous TK gene
- Allogeneic Turbo Chimeric Antigen Receptor (Turbocar) T Cells Targeting B Cell Maturation Antigen
- Allogeneic ex vivo expanded umbilical cord blood cells
- Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus
- Allogeneic umbilical cord blood cells treated ex vivo with 16,16-dimethyl prostaglandin E2
- Alvocidib
- Aplidine
- Arsenic trioxide
- Autologous CD3+ T cells transduced with retroviral vector containing a chimeric antigen receptor directed against CD19 (Autologous CD3+ T cells containing CD19 chimeric antigen receptor)
- Autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor
- Autologous CD4+ and CD8+ T cells genetically modified with a lentiviral vector encoding a B-cell maturation antigen-specific chimeric antigen receptor
- Autologous Epstein-Barr virus specific T cells derived from peripheral blood mononuclear cells, expanded ex vivo-
- Autologous T cells ex vivo modified with a lentiviral vector encoding a chimeric antigen receptor specific for CD1a
- Autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD123
- Autologous T cells transduced with lentiviral vector containing a tandem chimeric antigen receptor directed against CD20 and CD19
- Autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human B cell maturation antigen with 4-1BB and CD3-zeta intracellular signalling domains
- Autologous T-Cells transduced with a lentiviral vector (LVV) expressing CD20-specific chimeric antigen receptor (CAR) gene
- Autologous T-cells transduced with a lentiviral vector encoding a chimeric antigen receptor against CD7
- Autologous T-cells transduced with lentiviral vector encoding an anti-SLAMF7 CD28/CD3-zeta chimeric antigen receptor
- Autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6) (also termed ssCART-19 cells)
- Autologous ex-vivo-expanded peripheral polyclonal lymphocytes enriched in activated natural killer cells (CellProtect)
- Autologous human T cells genetically modified ex-vivo with a lentiviral vector encoding a chimeric antigen receptor for B-cell maturation antigen
- Autologous human peripheral blood Vdelta1+ T lymphocytes activated in vitro by cytokine and monoclonal antibody treatment
- Autologous tumour-derived immunoglobulin idiotype coupled to keyhole limpet haemocyanin
- Axicabtagene ciloleucel
- B-cell maturation antigen (BCMA)-directed, genetically engineered T cell immunotherapy product derived from an autologous leukapheresis
- Belantamab mafodotin
- Belinostat
- Bendamustine for 50 ml admixture
- Bendamustine-vorinostat fusion molecule
- Besilesomab
- Betalutin (177Lu-tetraxetan-tetulomab)
- Birtamimab
- Bispecific, biparatopic antibody targeting CD38 and CD47
- Blinatumomab
- Bortezomib
- Brentuximab vedotin
- Brexucabtagene autoleucel
- Carboxy pyrrolidine hexanoyl pyrrolidine carboxylate
- Carfilzomib
- Cenersen
- Cevostamab
- Chimeric antigen receptor (CAR)-T cell therapy targeting G protein-coupled receptor class-C group-5 member-D (GPRC5D)
- Chimeric fibril-reactive IgG1k monoclonal antibody 11-1F4
- Chimeric monoclonal antibody against kappa myeloma antigen
- Chlormethine
- Cladribine
- Clofarabine
- Copanlisib
- Crisantaspase
- Daratumumab
- Darinaparsin
- Dasatinib
- Denileukin diftitox
- Deoxyribose phosphorothioate (5´-tct-ccc-agc-gtg-cgc-cat-3´)
- Devimistat
- Dexamethasone (40 mg tablet)
- Dinaciclib
- Doxorubicin hydrochloride (liposomal)
- Duvelisib
- EBV-induced natural T cell [EBViNT Cell]
- Elotuzumab
- Elranatamab
- Entinostat
- Entospletinib
- Enzastaurin
- Epcoritamab
- Epratuzumab
- Eryaspase
- Everolimus
- Fenebrutinib
- Fenretinide
- Filanesib
- Forodesine
- Forodesine hydrochloride
- Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A)
- Glofitamab
- Glucopyranosyl Lipid A (GLA)
- Hematopoietic stem and progenitor cells expanded ex-vivo with a low molecular weight aryl hydrocarbon receptor (AHR) antagonist
- Hemi L-glutarate salt of 7-[(3R,4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5- dihydro-pyrrolo [3,2-d] pyrimidin-4-one
- Human anti-intercellular adhesion molecule-1 monoclonal antibody
- Human monoclonal antibody against CD4
- Human monoclonal antibody against HLA-DR
- Humanised Fc engineered monoclonal antibody against CD19
- Humanised IgG1 monoclonal antibody against human KIR3DL2
- Humanised IgG1 monoclonal antibody against the extracellular domain of receptor tyrosine kinase-like orphan receptor 1 coupled via a proteolytically cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate linker to monomethyl auristatin E
- Humanised agonistic anti-CD28 monoclonal antibody
- Humanised anti-CD37 monoclonal antibody conjugated to maytansinoid DM1
- Humanised anti-HM1.24 monoclonal antibody
- Humanised anti-human Interleukin-6 (IL-6) receptor monoclonal antibody (Genetic Recombination)
- Humanised monoclonal antibody against CD38
- Humanised single chain monoclonal antibody against CD37
- Ibrutinib
- Idelalisib
- Imatinib mesilate
- Imexon
- Imvotamab
- Inecalcitol
- Inotuzumab ozogamicin
- Iodine (123I) Serum Amyloid P
- Iodine (124I) evuzamitide
- Iodine (131I) tositumomab
- Ixazomib
- L-Asparaginase
- Lenalidomide
- Ligand binding moiety to STAT3, a chemical linker, and a ligand binding moiety to an E3 ligase that leads to STAT3 degradation
- Loncastuximab Tesirine
- Lumiliximab
- Lutetium (177LU) lilotomab satetraxetan
- Marizomib
- Masked immunocytokine (MIC) comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2a
- Mavorixafor
- Maytansinoid-conjugated humanized monoclonal antibody against CD56
- Meclorethamine
- Melphalan
- Mercaptopurine (oral liquid)
- Mercaptopurine (oral suspension)
- Methotrexate (oral liquid)
- Milatuzumab
- Miltefosine
- Mocetinostat
- Mogamulizumab
- Monoclonal antibody to human interleukin-6
- Moxetumomab pasudotox
- Murine anti-CD22 antibody variable region fused to truncated Pseudomonas exotoxin 38
- N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide
- N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin)benzamide
- N-(3,4-dihydroxyphenyl)-3,4-dihydroxybenzamide
- N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole
- N2'-Deacetyl-N2'-[4-methyl-4-(oxobuthyldithio)-1-oxopentyl]-maytansine-chimerized anti- CD138 IgG4 monoclonal antibody
- Naloxone hydrochloride dihydrate
- Nanatinostat, valganciclovir
- Nelarabine
- Niraparib
- Nivolumab
- Obecabtagene autoleucel
- Obinutuzumab
- Odronextamab
- Ofatumumab
- Olverembatinib
- Oprozomib
- Panobinostat
- Parsaclisib
- Pegaspargase
- Pegylated L-asparaginase
- Pegylated recombinant Erwinia chrysanthemi L-asparaginase
- Perifosine
- Pirtobrutinib
- Pivekimab sunirine
- Pixantrone dimaleate
- Plitidepsin
- Polatuzumab vedotin
- Pomalidomide
- Ponatinib
- Positive transcription elongation factor b (PTEFb) inhibitor
- Pralatrexate
- Recombinant anti-CD3-bi-single-chain-Fv-diphtheria toxin fusion protein
- Recombinant anti-CD40 monoclonal antibody
- Recombinant antibody construct against human CD30 and CD16A
- Recombinant antibody derivative against human CD19 and CD3
- Recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory protein alpha (SIRPa) linked to the IgG4 Fc region of human IgG
- Recombinant glycoprotein gp350 of Epstein-Barr virus
- Recombinant histidine-tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors
- Recombinant human histone H1.3 and recombinant human N-bis-met-histone H1.3
- Recombinant human monoclonal IgM antibody targeting glucose-regulated protein 78
- Recombinant monoclonal antibody to human serum amyloid P component
- Reduced oxidised N-acetyl heparin
- Resiquimod
- Resminostat
- Rituximab
- Romidepsin
- S-[5-(omega-methoxypoly(oxyethylene)-2-oxopentyl)]-L-cysteinylglycyl-L-serinylglycylgylcyl-L-isoleucyl-L-lysyl-L-glutamyl-L-phenylalanyl-L-leucyl-L-glutaminyl-L-arginyl-L-phenylalanyl-L-isoleucyl-L-histyl-L-isoleucyl-L-valyl-L-glutaminyl-L-serinyl-L-isoleucyl-L-isoleucyl-L-asparaginyl-L-threonyl-L-serinamide, acetate salt
- Selinexor
- Siltuximab
- Sintilimab
- Siplizumab
- Spanlecortemlocel
- Spebrutinib
- Stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells
- Suberolylanilide hydroxamic acid
- Synthetic hypericin
- Synthetic signal peptide of human Mucin-1 (amino acids 1-21)
- Talquetamab
- Tazemetostat
- Teclistamab
- Temsirolimus
- Thalidomide
- Therapeutic Inducers of Natural Killer cell Killing Immunotherapy expanded from cord blood-derived hematopoietic progenitors
- Tipifarnib
- Tisagenlecleucel
- Tositumomab
- Triterpenoid saponin
- Ublituximab
- Valemetostat Tosylate
- Valproic acid, sodium
- Veltuzumab
- Vemurafenib
- Venetoclax
- Vincristine sulfate liposomes
- Vorinostat
- Wilms' tumour 1 (WT1) vaccine
- Yttrium (90Y) antiferritin polyclonal antibodies
- Zanolimumab
- Zanubrutinib
- allogeneic anti-Epstein Barr virus cytotoxic lymphocytes expanded ex vivo
- bimiralisib
- florbetaben (18F)
- haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate
- melphalan flufenamide
- oligonucleotide inhibitor of microRNA miR-155-5p
- tagraxofusp
Obchodní název
- ADCETRIS
- ADRIBLASTINE
- ALIQOPA
- ALKERAN
- ANTI-HUMAN INTERLEUKIN-6 (IL-6) RECEPTOR MONOCLONAL ANTIBODY (GENETICAL RECOMBINATION) CHUGAI PHARMACEUTICAL CO LTD
- ARACYTINE
- ARRANON
- ARZERRA
- ATRIANCE
- Abecma
- BELEODAQ
- BENDEKA
- BESPONSA
- BICNU
- BLINCYTO
- BLITZIMA
- BORTEZOMIB ACCORD
- BORTEZOMIB FRESENIUS KABI
- BORTEZOMIB HOSPIRA
- BORTEZOMIB SUN
- BREYANZI
- BRUKINSA
- Blenrep
- CAELYX pegylated liposomal
- CALQUENCE
- CAMPATH
- CARMUSTINE OBVIUS
- CELDOXOME PEGYLATED LIPOSOMAL
- CHLORAMINOPHENE
- CLOLAR
- COPIKTRA
- COTELLIC
- Carvykti
- DARZALEX
- DASATINIB ACCORD
- DASATINIB ACCORDPHARMA
- DOXIL
- Darzalex Faspro
- EBVALLO
- ELZONRIS
- EMPLICITI
- ENDOBULINE
- ERWINASE
- EVOLTRA
- EVOMELA
- FARYDAK
- FOLOTYN
- GAMMAGARD
- GAZYVA
- GAZYVARO
- GLEEVEC
- GLIVEC
- HEMADY
- HOLOXAN
- ICLUSIG
- IMATINIB TEVA
- IMATINIB TEVA B.V.
- IMBRUVICA
- IMNOVID (previously POMALIDOMIDE CELGENE)
- INTRONA
- ISTODAX
- IVOZALL
- Imatinib Koanaa
- JAYPIRCA
- JYLAMVO
- KEYTRUDA
- KIDROLASE
- KYMRIAH
- KYPROLIS
- LEDERTREXATE
- LENALIDOMIDE ACCORD
- LENALIDOMIDE KRKA
- LENALIDOMIDE KRKA D.D.
- LENALIDOMIDE KRKA D.D. NOVO MESTO
- LITAK
- LUMOXITI
- LUNSUMIO
- Ledaga
- Lenalidomide Mylan
- MABTHERA
- MARQIBO
- MELADININE
- MINJUVI
- MONJUVI
- MOZOBIL
- NEOFORDEX
- NINLARO
- Nexpovio
- OCTAGAM
- ONCASPAR
- OPDIVO
- PEGASPAR
- PEPAXTI
- PIXUVRI
- PLERIXAFOR ACCORD
- POLIVY
- POMALYST
- POTELIGEO
- PURIXAN
- Pepaxto
- Phelinun
- REVLIMID
- RITEMVIA
- RITUXAN
- RITUXAN HYCELA
- RITUZENA
- RIXATHON
- RIXIMYO
- ROFERON A
- Ruxience
- Rylaze
- SANDOGLOBULINE
- SARCLISA
- SPECTRILA
- SPRYCEL
- SYLVANT
- Sarclisa
- TARGRETIN
- TAZVERIK
- TECVAYLI
- TEGELINE
- THALIDOMIDE BMS
- THALIDOMIDE LIPOMED
- THALOMID
- TORISEL
- TRUXIMA
- Tecartus
- Thiotepa Riemser
- Ukoniq
- VALCHLOR
- VELBE
- VELCADE
- VENCLEXTA
- VENCLYXTO
- XALKORI
- XALUPRINE
- XPOVIO
- YESCARTA
- ZEVALIN
- ZOLINZA
- ZOLSKETIL pegylated liposomal
- ZYDELIG
- Zynlonta